Zach Jonasson PhD
Managing General Partner
Dr. Jonasson is a Managing General Partner and co-founder of PVP. He leads PVP’s investment strategy in life sciences and healthcare verticals. Dr. Jonasson brings over 25 years of experience in venture capital, entrepreneurship, and start-up operations. He was the co-founder and initial CEO of ReForm Biologics, a start-up developing next generation formulations technologies for biotherapeutics, and a cofounder of Crop Enhancement, a start-up developing sustainable chemicals for pre- and post-harvest crop protection. Previously, he was a General Partner and Kauffman Fellow at Seaflower Ventures. Dr. Jonasson’s current investments include Lucira Health (LHDX), AbSci (ABSI), L7 Informatics, Sentinel Monitoring Systems. His prior investments include Totient (acquired by AbSci), Serenex (acquired by Pfizer), MetaWorks (acquired by UBC), Valeritas (ZEAL), TelMed IQ (acquired by PerfectServe), and Dark Vision (acquired by Koch Industries).
Dr. Jonasson earned a BS from Georgetown University’s Honor Program and an AM and PhD from Harvard University, where he was a Sackler Scholar pursuing research into the neurobiology underlying learning and memory processes. While a graduate student, he taught market research methods at Harvard Business School and was the fifth hire at Risk Capital Management (acquired by Towers Perrin). In addition to his investment and board roles at PVP, Dr. Jonasson serves on the board of the Oregon Translational Research and Development Institute (OTRADI), on the Commercialization Council of the Oregon Nanoscience and Microtechnologies Institute (ONAMI), and on the Advisory Board of the Life Sciences Institute at the University of British Columbia. Dr. Jonasson is based in Seattle where he enjoys hiking and kayaking with his wife and two children.
Sectors: Life Sciences, Healthcare, Synthetic Biology and anything inspired by biology
Stages: Seed, Venture, Growth